Ensitrelvir and Cariprazine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Cariprazine
Ensitrelvir
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Cariprazine (Vraylar) and ensitrelvir should not be taken together. Ensitrelvir blocks a liver enzyme called CYP3A that your body uses to break down cariprazine. When that enzyme is slowed down, cariprazine can build up to higher levels than normal.
Higher cariprazine levels can mean stronger side effects, like sleepiness, dizziness, restlessness, muscle stiffness, or unusual movements. Because this combination is considered off-limits, please don't stop or change either medicine on your own. Talk with your pharmacist or doctor. They can plan the safest timing or pick a different option, and this is very manageable with their help.
Contraindicated combination. Ensitrelvir is a strong CYP3A inhibitor; cariprazine is a CYP3A substrate (not a prodrug). Inhibition of CYP3A-mediated metabolism is expected to increase cariprazine exposure and its active metabolites, raising the risk of dose-related adverse effects (EPS, akathisia, sedation, QT considerations).
- Direction: increased cariprazine exposure (AUC/Cmax).
- Magnitude: not quantified for cariprazine; ensitrelvir raised midazolam AUC ~6.8-fold.
- Evidence: probable.
- Management: avoid concurrent use. Initiate ensitrelvir only after evaluating the substrate; account for prolonged CYP3A inhibition (effects persist days after last dose) before reinitiating cariprazine.
What happens
Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects
Interaction Deep Dive
Giving ensitrelvir together with CYP3A substrates is contraindicated because it can raise the exposure of those substrates and lead to adverse effects. In drug interaction studies, when midazolam (a CYP3A substrate) was given as a single 2 mg oral dose alongside ensitrelvir at the clinical dose (375 mg on day 1 and 125 mg on days 2 to 5), administration on Day 5 produced roughly a 2.80-fold rise in midazolam Cmax and a 6.77-fold rise in its AUC(0 to inf) relative to midazolam given by itself. Similarly, co-administration of a single 1 mg dose of dexAMETHasone with ensitrelvir (750 mg on day 1 and 250 mg on days 2 to 5, twice the recommended dose) on day 5, and dexAMETHasone given alone on day 9 (5 days after the final ensitrelvir dose) and day 14 (10 days after the final ensitrelvir dose), yielded about a 1.47-fold increase in Cmax and a 3.47-fold increase in AUC(0 to inf) of dexAMETHasone on day 5, a 1.24-fold increase in Cmax and a 2.38-fold increase in AUC(0 to inf) on day 9, and a 1.17-fold increase in Cmax and a 1.58-fold increase in AUC(0 to inf) on day 14, each compared with dexAMETHasone administered alone. Start ensitrelvir only after a careful review of the pertinent clinical and pharmacokinetic factors tied to the concomitant medication. Furthermore, base any reintroduction of contraindicated CYP3A substrates on an evaluation of how long CYP3A inhibition persists together with patient specific considerations1.
Why it happens (mechanism)
Inhibition of CYP3A-mediated metabolism by ensitrelvir
How to manage this interaction
This pairing is contraindicated, so the goal is to avoid taking them at the same time. Your care team manages this, not you, so keep taking your prescribed medicines and don't make changes on your own.
- Tell your pharmacist and prescriber you take cariprazine (Vraylar) before ensitrelvir is started.
- Your team may hold or adjust one medicine and choose safer timing or an alternative.
- Because ensitrelvir's enzyme-blocking effect can linger for several days after the last dose, your team decides when it's safe to restart cariprazine.
- Report any new drowsiness, dizziness, restlessness, or muscle stiffness.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) Giving midazolam (a CYP3A substrate) as a single 2 mg oral dose together with ensitrelvir at the clinical dose (375 mg on day 1 and 125 mg on days 2 to 5) on Day 5 produced roughly a 2.80-fold rise in midazolam Cmax and a 6.77-fold rise in midazolam AUC(0 to inf) relative to midazolam given by itself. In addition, co-administration of dexAMETHasone (a single 1 mg dose) with ensitrelvir (750 mg on day 1 and 250 mg on days 2 to 5, twice the recommended dose) on day 5, and dexAMETHasone given alone on day 9 (5 days after the final ensitrelvir dose) and day 14 (10 days after the final ensitrelvir dose), produced approximately a 1.47-fold rise in Cmax and a 3.47-fold rise in AUC(0 to inf) of dexAMETHasone on day 5, a 1.24-fold rise in Cmax and 2.38-fold rise in AUC(0 to inf) on day 9, and a 1.17-fold rise in Cmax and a 1.58-fold rise in AUC(0 to inf) on day 14, compared with dexAMETHasone given by itself 1.
Common questions
Can I take Ensitrelvir and Cariprazine together?
Taking cariprazine (Vraylar) with ensitrelvir is contraindicated because ensitrelvir can markedly raise cariprazine levels and side effects; do not combine them, and let your pharmacist or doctor coordinate timing or an alternative. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Ensitrelvir and Cariprazine interaction?
It is rated contraindicated. These should generally not be used together.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Ensitrelvir and Cariprazine interaction managed?
This pairing is contraindicated, so the goal is to avoid taking them at the same time. Your care team manages this, not you, so keep taking your prescribed medicines and don't make changes on your own. Tell your pharmacist and prescriber you take cariprazine (Vraylar) before ensitrelvir is started. Your team may hold or adjust one medicine and choose safer timing or an alternative. Because ensitre… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Ensitrelvir or Cariprazine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: XOCOVA® oral tablets, ensitrelvir oral tablets. Shionogi Inc. Florham Park, NJ, 2026. DailyMed
Keep reading about Cariprazine
Keep reading about Ensitrelvir
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist